Hess H J, Graham R M, Homcy C J
Proc Natl Acad Sci U S A. 1983 Apr;80(8):2102-6. doi: 10.1073/pnas.80.8.2102.
An azide analog, 2-[4-(4-azidobenzoyl)piperazin-1-yl]-4-amino-6, 7-dimethoxyquinazoline (CP59,430), of the highly selective alpha 1-adrenergic receptor antagonist prazosin was synthesized and its effects on rat hepatic membrane and affinity-purified alpha 1-adrenergic receptor preparations were examined. CP59,430 behaved as a competitive antagonist before photolysis. When the membrane or purified preparations pretreated with CP59,430 were irradiated with UV light, CP59,430 behaved as a noncompetitive antagonist. Labeling of membrane alpha 1-adrenergic receptors was irreversible; repeated dialysis or washing could not reverse the photolysis-induced inactivation by CP59,430, whereas dialysis completely reversed the antagonism by the same concentration of the label prior to photolysis. Additionally, photolabeling of purified receptors was resistant to Sephadex G-50 chromatography, whereas in the absence of photolysis the same concentration of CP59,430 or prazosin (10 microM) could be readily removed by this procedure. CP59,430 appears to label specifically only alpha 1-adrenergic receptors because prazosin protected the membrane and purified receptors from photolysis-induced inactivation by CP59,430. Furthermore, specific [3H]dihydroalprenolol and [3H]yohimbine binding to membrane beta- and alpha 2-adrenergic receptors, respectively, was unchanged by CP59,430 at 1 microM, a concentration that decreased specific [3H]prazosin binding to alpha 1-adrenergic receptors by 72%. In additional studies, the photolysis-induced receptor inactivation by CP59,430 remained unchanged in the presence of the scavenger p-aminobenzoic acid. It is likely, therefore, that receptor labeling by CP59,430 occurs via a true photoaffinity mechanism. CP59,430, which specifically and irreversibly labels the alpha 1-adrenergic receptor after photolysis, should thus be uniquely valuable for the molecular characterization of this receptor.
合成了高选择性α1 -肾上腺素能受体拮抗剂哌唑嗪的叠氮类似物2 - [4 - (4 - 叠氮苯甲酰基)哌嗪 - 1 - 基]-4 -氨基 - 6,7 -二甲氧基喹唑啉(CP59,430),并检测了其对大鼠肝细胞膜和亲和纯化的α1 -肾上腺素能受体制剂的作用。CP59,430在光解前表现为竞争性拮抗剂。当用CP59,430预处理的膜或纯化制剂用紫外光照射时,CP59,430表现为非竞争性拮抗剂。膜α1 -肾上腺素能受体的标记是不可逆的;反复透析或洗涤不能逆转CP59,430引起的光解诱导失活,而透析能完全逆转相同浓度的标记物在光解前的拮抗作用。此外,纯化受体的光标记对Sephadex G - 50层析有抗性,而在无光解的情况下,相同浓度的CP59,430或哌唑嗪(10μM)可通过该方法轻易去除。CP59,430似乎仅特异性标记α1 -肾上腺素能受体,因为哌唑嗪可保护膜和纯化受体免受CP59,430引起的光解诱导失活。此外,在1μM浓度下,CP59,430对膜β -肾上腺素能受体和α2 -肾上腺素能受体分别与特异性[3H]二氢阿普洛尔和[3H]育亨宾的结合没有影响,该浓度使α1 -肾上腺素能受体与特异性[3H]哌唑嗪的结合减少了72%。在进一步的研究中,在清除剂对氨基苯甲酸存在的情况下,CP59,430引起的光解诱导受体失活保持不变。因此,CP59,430很可能通过真正的光亲和机制进行受体标记。光解后特异性且不可逆地标记α1 -肾上腺素能受体的CP59,430,因此对于该受体的分子表征应具有独特的价值。